0758 GMT - Parkway Life REIT is likely on a solid growth trajectory, DBS Group Research analysts say in a research report, as they maintain its buy rating on the REIT. The full earnings impact of the REIT's recent acquisition of a portfolio of French nursing homes is expected to emerge this year, the analysts say. Also, the rental upside for the REIT's Singapore hospitals should kick in from 2026, thanks to their master-lease renewal. Moreover, there's potential further upside to its Mount Elizabeth Orchard hospital's revenues post-asset enhancement initiative in 2026. However, DBS trims the unit's target price to S$4.75 from S$4.80 to reflect some adjusted assumptions. Units are 1.0% lower at S$3.94. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
February 10, 2025 02:58 ET (07:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.